Immune checkpoint inhibitors (ICIs) are mAbs against cytotoxic T-lymphocyte antigen 4 (CTLA-4), programmed death-1 receptor (PD-1) and programmed death-ligand 1 (PD-L1), which the inhibitory pathways that leads to T cell inactivation. Here, we report a case of ICI-induced immune-mediated hepatotoxicity with liver biopsy. A 63-year-old man with brain metastasis from lung adenocarcinoma was treated with three times of g knife treatment, following by a combination of chemotherapy [carboplatin and (550 mg) + pemetrexed (1000 mg)] plus bevacizumab (anti-VEGF monoclonal antibody) (600 mg D1) and camrelizumab (anti-PD-1 mAb) (200 mg D1). Around 21 days later, abnormal liver function was detected. He received a diagnosis of ICI-induced liver injury after liver biopsy. The liver function of this patient was recovered, following methylprednisolone treatment. Such data offers useful information for clinicians to deal with cancer patients for ICI treatment, suggesting that liver function must be closely monitored.